[Clinical study on buyang huanwu decoction to the metabolic imbalance of endothelin and calcitonin gene related peptide in patients with early cerebral infarction]

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in this randomized controlled trial publication.

To explore the mechanism of Buyang Huanwu Decoction (BHD) in treating early cerebral infarction.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

The levels of endothelin (ET) and calcitonin gene related peptide (CGRP) in plasma before and after treatment and the results of clinical treatment were observed, and also controlled with healthy subjects.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

Seventy cases with early cerebral infarction were randomly divided into two groups.

Chinese medicine group (CMG, n = 35) was treated with BHD; western medicine group (WMG, n = 35) was treated with hydroxyethyl starch injection and enteric coated aspirin tablets.

What Was Measured

The subject headings attached to it are Calcitonin Gene-Related Peptide, Cerebral Infarction, Drugs, Chinese Herbal and Endothelins.

What This Means in Plain Language

The paper is a randomized study of CGRP (Calcitonin Gene-Related Peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine), a journal based in China.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.